PEAK6’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
Other funds holding CRSP
PEAK6's CRSP Position: Q3 2026 in Review
PEAK6 increased its CRISPR Therapeutics (CRSP) stake by 66% in Q3 2026, buying an estimated $793K and bringing the position to 37,011 shares worth $2.05M. The position accounts for ﹤0.01% of the portfolio, ranked #1238.
PEAK6 first reported a position in CRSP in Q1 2025 and has held it in 5 quarters since. The position peaked at $5.17M in Q1 2026. 502 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.
- PEAK6 held 37,011 shares of CRISPR Therapeutics worth $2.05M as of Q3 2026.
- PEAK6 bought 14,695 CRISPR Therapeutics shares in Q3 2026, an estimated $793K.
- CRISPR Therapeutics made up ﹤0.01% of PEAK6's portfolio in Q3 2026, its #1238 holding.
- PEAK6 first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 5 quarters since.
- PEAK6's CRISPR Therapeutics position peaked at $5.17M in Q1 2026.
- 502 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.
Based on PEAK6's 13F filing for Q3 2026, filed 13 Nov 2026.